Request Demo
Last update 10 May 2025
Tilpisertib
Last update 10 May 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms GS-4875 |
Target |
Action inhibitors |
Mechanism TPL2 inhibitors(Mitogen-activated protein kinase kinase kinase 8 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC33H33ClN8O |
InChIKeyVFGSKBLZRDRHOI-ZAGPDIDGSA-N |
CAS Registry2065153-41-3 |
Related
1
Clinical Trials associated with TilpisertibNCT04130919
A Phase 2, Blinded, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-4875 in Subjects With Moderately to Severely Active Ulcerative Colitis
100 Clinical Results associated with Tilpisertib
Login to view more data
100 Translational Medicine associated with Tilpisertib
Login to view more data
100 Patents (Medical) associated with Tilpisertib
Login to view more data
100 Deals associated with Tilpisertib
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Colitis, Ulcerative | Phase 2 | United States | 20 Dec 2019 | |
| Colitis, Ulcerative | Phase 2 | Australia | 20 Dec 2019 | |
| Colitis, Ulcerative | Phase 2 | Austria | 20 Dec 2019 | |
| Colitis, Ulcerative | Phase 2 | Canada | 20 Dec 2019 | |
| Colitis, Ulcerative | Phase 2 | France | 20 Dec 2019 | |
| Colitis, Ulcerative | Phase 2 | Germany | 20 Dec 2019 | |
| Colitis, Ulcerative | Phase 2 | Italy | 20 Dec 2019 | |
| Colitis, Ulcerative | Phase 2 | Poland | 20 Dec 2019 | |
| Colitis, Ulcerative | Phase 2 | Switzerland | 20 Dec 2019 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 2 | 19 | (Tilpisertib 300 mg (Blinded Treatment Phase)) | gdehcjkgee = lwxgxrierp qywywtajib (pnipbqnobl, pebjltwvfs - gcyvmntlyb) View more | - | 24 Aug 2022 | ||
(Tilpisertib 100 mg (Blinded Treatment Phase)) | gdehcjkgee = wmoxhhzceh qywywtajib (pnipbqnobl, dczkeivtex - kdasblkiui) View more | ||||||
Not Applicable | - | bikhwjwgtk(dkhvshckbg) = cadkicdtgn advokpdnya (vxtsfkaxfm ) | Positive | 10 Nov 2019 | |||
Not Applicable | - | - | aihhidnnvd(wumilmgpes) = vzlxizadtu piyxbuksnr (nucqvucjts ) | - | 01 Oct 2019 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free